Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in Post-Transplantation Diabetes Mellitus
2016-001580-37Phase 2Completed
- Sponsor
- Medical University of Vienna
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of empagliflozin in post-transplantation diabetes mellitus (PTDM) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Medical University of Vienna. Primary endpoint: Change in 2-hour OGTT glucose after 1 month. Started Nov 2016; status: completed.
02
Drugs
empagliflozin
03
Conditions
post-transplantation diabetes mellitus (PTDM)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2016-001580-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001580-37.